ACCORDING to the US Food and Drug Administration (FDA), how well consumers and healthcare professionals are able to identify deceptive information plays a role in the agency's enforcement approach.
"Reports of deceptive promotion are useful to FDA because they allow investigators to focus their efforts in an era where the amount of promotion far exceeds the resources available to monitor everything," FDA says.
Consequently the FDA says it will conduct two studies which will include patients and physician populations.
An independent agency will develop dummy advertisements and test consumer and physician reactions on both implicit and explicit claims.
Perhaps not surprisingly, drug companies have been critical of such studies in the past, the Regulatory Affairs Professionals Society (RAPS) said.
"The ability to identify such promotion has important public health implications," FDA says.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jan 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jan 17
